GDF-15 LEVEL CHANGES IN EARLY AND LATE PERIOD AFTER CATHETER ABLATION OF ATRIAL FIBRILLATION (YOUNG INVESTIGATOR AWARD COMPETITION)

B. Steklá, J. Marek, J. Šimek, M. Dusík, Z. Fingrová, A. Linhart, Š. Havránek (Praha)
Tématický okruh: Poruchy rytmu, kardiostimulace
Typ: Ústní sdělení - lékařské, CCVRID 2023

Introduction: GDF-15 (growth differentiation factor 15) is protein from transforming growth factor β (TGF-β) cytokine family. In patients with atrial fibrillation (AF) GDF-15 is a potent marker of bleeding adverse events in anticoagulated patients and a predictor of overall mortality. Aim of the study was to describe how catheter ablation of atrial fibrillation affects GDF-15 levels in early and late period and analyse impact of used technology.

Methods: We enrolled 48 patients (median 62 (50; 68) years, 30 males) undergoing radiofrequency catheter ablation (RFCA) of AF who underwent 6 sequential blood takes (before RFCA – baseline, right after RFCA (0 hr), 24 and 48 hours after RFCA, 90 and 180 days after RFCA) to analyse GDF-15 level. In parallel, other conventional biomarkers were obtained: N-terminal fragment brain natriuretic factor (NT-proBNP) and high sensitivity cardiac troponin T (TnT). The results were compared to 22 patients (median 63 (52; 65) years, 13 males) treated with pulsed field ablation (PFA).

Results: The dynamics of GDF-15 levels is visualised in Figure. GDF-15 level peak was registered 48 hours after ablation with median (IQR) 1183 ng/l (824; 1988). After 90 days from ablation there still persisted higher GDF-15 levels in relation to input levels (p

Conclusion: Even though GDF-15 is considered as a nonspecific biomarker reflecting general condition of patient, the levels are significantly affected by interventional treatment of AF. PFA seems to cause higher elevation of TnT than RFA.